Associated tags: ARC, AI, Microelectromechanical systems, Teleradiology, LTD, Radiology, Health, Medical Devices, File, Maintenance, Research, Patient
MD,
NANO,
Joint Commission,
Commission,
Accreditation,
Patient,
Gold,
Health,
Gold Seal,
MBA,
LTD,
Teleradiology,
Organization,
Joint,
Nursing PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its wholly-owned subsidiary, USARAD Holdings, Inc., a leading provider of teleradiology services, has earned The Joint Commission’s Gold Seal of Approval® for Ambulatory Health Care Accreditation for the sixth time by demonstrating continuous compliance with its performance standards.
Key Points:
- The Gold Seal is a symbol of quality that reflects a health care organization’s commitment to providing safe and quality patient care.
- The Joint Commission’s standards are developed in consultation with health care experts and providers, measurement experts and patients.
- They are informed by scientific literature and expert consensus to help health care organizations measure, assess and improve performance.
- “The Joint Commission is one of the world's most trusted medical accreditation organizations.
PETACH TIKVA, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announces that Company management will participate in three investor conferences in the month of May 2024:
Key Points:
PETACH TIKVA, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announces that Company management will participate in three investor conferences in the month of May 2024:
PETACH TIKVA, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (“SEC”) on April 22, 2024.
Key Points:
- PETACH TIKVA, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (“SEC”) on April 22, 2024.
- The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at https://www.sec.gov/ and on the Company’s website at https://www.nanox.vision/ under “Financials” in the Investors section.
- The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request.
- Requests should be directed to Investor Relations, at [email protected].
Diagnosis,
X-ray,
LTD,
Cardiology,
Patient,
Science,
Radiology,
SCL,
Department of Tourism (Philippines),
NANO,
Teleradiology,
ARC,
Marketing,
Medical device PETAH TIKVA, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced a new collaboration to advance the Nanox.ARC 3D imaging system and Nanox artificial intelligence (AI) solutions in Korea with AhealthZ – a distributor of healthcare services and devices – and SCL Science, AhealthZ’s affiliated company and subsidiary of global healthcare group SCL (Seoul Clinical Laboratories).
Key Points:
- Under the collaboration, AhealthZ plans to assist Nanox in efforts to secure local authorizations and licenses to enable the importation, marketing and sales of the Nanox.ARC in South Korea.
- The Nanox.ARC is a digital tomosynthesis system that uses multiple sources of X-rays to produce a three-dimensional, tomographic images.
- The collaboration will also include SCL Science integrating Nanox’s AI solutions in remote image analysis and other operations.
- “We are excited to work with AhealthZ and SCL Science to bring our comprehensive medical imaging solutions to South Korea, a country of over 51 million people and one of the world’s most advanced technological markets,” said Erez Meltzer, Nanox Chief Executive Officer.
Research,
PIN,
LTD,
Intermountain Health,
Radiology,
Exercise,
Medical imaging,
Patient,
Health,
Fatty liver disease,
Action Replay,
Policy,
Sale,
AI,
D&O,
Google Images,
Teleradiology,
NANO,
GAAP,
ARC,
Depreciation,
Marketing,
FDA,
Vertebral compression fracture,
Hand,
Cryptocurrency PETAH TIKVA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2023 and provided a business update.
Key Points:
- Fourth Quarter 2023 Highlights and Recent Developments:
Generated $2.4 million in revenue in the fourth quarter of 2023, compared to $2.1 million in the fourth quarter of 2022.
- “I am incredibly proud to announce another strong quarter and year for Nanox,” said Erez Meltzer, Nanox Chief Executive Officer.
- “First and foremost, we achieved a pivotal milestone in fiscal year 2023, getting FDA clearance for the Nanox ARC systems and deploying them in the key US market.
- During the fourth quarter of 2023, Nanox AI continued to complete pilot programs with marketplaces, marketplace costumers and health organizations in anticipation of full deployment of its products.
PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024.
Key Points:
- PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024.
- Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m.
- Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration .
- You may access the live webcast of the conference call by using the following link: Nanox Q4 Earnings Call Webcast .
Syndrome,
Health,
National Health Service,
ROI,
Congress,
LTD,
Rheumatology,
Bone disease,
Data analysis,
Risk,
Patient,
Fracture,
VCF,
NHS,
Abdomen,
Hospital,
Research,
AI,
University,
Systematic review,
Treatment,
Spine,
FLS,
Family,
FDA,
Vertebral compression fracture,
University of Oxford,
Medical device PETACH TIKVA, Israel, March 12, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, and its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd. (Nanox.AI), today announced that early findings from the AI-enabled Detection of OsteoPorosis for Treatment (ADOPT) study, which uses a Nanox.AI artificial intelligence solution, HealthVCF, to review routine CT scans, have identified up to six times more patients with vertebral compression fracture than the national average at National Health Services (NHS) hospitals in the UK, which include University of Oxford and other healthcare centers.
Key Points:
- Thus far in the study, the Nanox.AI algorithm has identified over 2,400 patients with VCF from routine CT scans that were not known to the NHS’s hospitals, and have since been flagged for follow-up assessments.
- “Leveraging AI-powered population health solutions presents an effective and efficient avenue for early identification of patients at very high risk of fractures, facilitating timely intervention and care.
- As such, there have been efforts to introduce FLS into public health systems.
- The next-generation HealthOST received FDA 510(K) clearance in April 2022.
Retrieved on:
Thursday, February 29, 2024
Clalit Health Services,
Medical imaging,
ARC,
3D,
Radiology,
X-ray,
Lung,
Radiation,
LTD,
Risk,
Beilinson,
Rabin Medical Center,
Patient,
Trial of the century,
CAC,
Partnership PETAH TIKVA, Israel, Feb. 29, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, and Beilinson Hospital, a leading Israeli hospital and part of Rabin Medical Center, owned and operated by Israel’s largest healthcare organization, Clalit Health Services, today announced their collaboration to conduct a clinical study evaluating the Nanox.ARC 3D imaging system in a clinical outpatient setting at Beilinson Hospital. The study will specifically assess the diagnostic capabilities of the Nanox.ARC’s tomographic imaging system compared with conventional two-dimensional radiography for detection of lung and chest disease in adults. Such a study may help determine the clinical utility of the additional information provided by the 3D tomographic imaging, potentially preventing the need for more advanced imaging and exposure to additional radiation.
Key Points:
- The study will specifically assess the diagnostic capabilities of the Nanox.ARC’s tomographic imaging system compared with conventional two-dimensional radiography for detection of lung and chest disease in adults.
- The study is being led by Professor Eli Atar, M.D., FSIR, Director of the Department of Imaging, and Dr. Ahuva Grubstein, M.D., Department of Diagnostic Radiology, both at Beilinson Hospital.
- This study evaluating the Nanox.ARC is an addition to the existing collaboration between Nanox AI and Clalit, and the second study conducted with Beilinson Hospital.
- “This technology shows promise to expand clinicians’ capabilities for more precise readings and earlier detection across a range of pulmonary conditions.
Retrieved on:
Tuesday, February 13, 2024
DSM-IV codes,
Non-alcoholic fatty liver disease,
Coronary artery disease,
NAFLD,
CT scan,
Spine,
Artificial intelligence,
AI,
MD,
Osteoporosis,
American Journal,
Obesity,
FDA,
Cardiovascular disease,
Food,
Abdomen,
Risk,
Cirrhosis,
Hepatology,
Liver disease,
Prevalence,
University,
MASH,
Type 2 diabetes,
AJR,
Death,
The Company,
Patient,
Diagnosis,
Software,
CAC,
Medicine,
Medical imaging PETACH TIKVA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd., received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for HealthFLD, an artificial intelligence (AI) software that provides automated qualitative and quantitative analysis of liver attenuation from routine contrast and non-contrast chest and abdomen CT scans in patients between the ages of 18 to 75. HealthFLD is intended to support clinicians in the detection of fatty liver, correlated with hepatic steatosis, an early sign of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD).
Key Points:
- HealthFLD is intended to support clinicians in the detection of fatty liver, correlated with hepatic steatosis, an early sign of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD).
- MASLD is commonly asymptomatic until it progresses to advanced liver fibrosis, and the current gold standard for diagnosis is a liver biopsy, which is invasive and costly.
- HealthFLD was designed to help clinicians in the assessment and analysis of fatty liver in the general population from routine CT scans.
- It’s promising to have a liver solution available that may help evaluate early signs of illness from routine imaging.”
The HealthFLD clearance is the third product across the Nanox AI suite of population health solutions to receive FDA clearance.
Retrieved on:
Tuesday, January 16, 2024
Family,
ARC,
Chairperson,
Science,
Friends,
Environment,
Entrepreneurship,
Investment,
Health,
NANO,
LTD,
Management PETACH TIKVA, Israel, Jan. 16, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced that the Company’s founder and non-executive chairman, Ran Poliakine, passed away on Friday, Jan. 12, 2024, due to a medical condition.
Key Points:
- PETACH TIKVA, Israel, Jan. 16, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced that the Company’s founder and non-executive chairman, Ran Poliakine, passed away on Friday, Jan. 12, 2024, due to a medical condition.
- After founding Nanox and leading the effort to take the Company public in 2020, he moved to a non-executive role in 2021, handing leadership of Nanox to the current management team.
- Mr. Poliakine was instrumental in the early development of an end-to-end solution focused on applying proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable.
- “It is with great sadness that we mourn the loss of Ran, my friend and source of endless inspiration,” said Erez Meltzer, CEO of Nanox.
